NetworkNewsBreaks – Syros Pharmaceuticals, Inc.’s (NASDAQ: SYRS) Advancements in CDK Inhibition Featured in ROTH Equity Research Report

February 3, 2020 13:45:57

Syros Pharmaceuticals (NASDAQ: SYRS) was featured in a recent Equity Research Report published by ROTH Capital Partners, LLC. The report reads, “Yesterday, Syros announced new preclinical data showcasing the differentiating therapeutic effects of its CDK7 vs CDK12/13 inhibitors. More broadly, the company highlighted its platform’s potential to identify genes and transcriptional regulators of cancer, which should enable the identification of new drug targets to further expand its pipeline of small-molecule inhibitors. With this update, coupled with the entry of Syros’ next-gen CDK7 inhibitor (SY-5609) into the clinic, we invite you to join our call with a renowned expert on gene regulation.” The report further provides details to RSVP for the KOL Call, scheduled for February 12, 2020, during which Whitehead Institute’s Professor of Biology, Richard A. Young, will speak on “Insights on the Outlook of Transcriptional CDKs in Cancer with a Focus on CDK7.”

To request access to the full report, visit

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust pipeline, including SY-1425, a first-in-class oral selective RARα agonist in a Phase 2 trial in a genomically defined subset of acute myeloid leukemia patients, and SY-5609, a highly selective and potent oral CDK7 inhibitor in a Phase 1 trial in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

NetworkNewsWire is part of the InvestorBrandNetwork.